195
Participants
Start Date
August 27, 2024
Primary Completion Date
April 1, 2026
Study Completion Date
December 15, 2026
VRDN-003
VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
Placebo
All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
Scheie Eye Institute Penn Presbyterian, Philadelphia
Wills Eye Hospital, Philadelphia
West Virginia University Eye Institute, Morgantown
Duke Eye Center, Durham
Asheville Clinical Research, Asheville
Agile Clinical Research Trials, LLC, Atlanta
Med-Care Research, Miami
Hype Clinical Research LLC, Miami
Anmed Health Services LLC, Miami
Southern Clinical Research LLc, Miami
Sarasota Retina Institute, Sarasota
Ilumina Medical Research, Kissimmee
Fraser Eye Care Center, Fraser
Kahana Oculoplastic & Orbital Surgery, Livonia
Vision Medical Research, Orland Park
University Health, Kansas City
Baylor College of Medicine/Alkek Eye Center, Houston
Gulf Coast Clinical Trials, Houston
Neuro-Eye Clinical Trials, Houston
Horizon Clinical Research Group, Cypress
Scottsdale Clinical Trials, Scottsdale
S.L. Office, Las Vegas
Vector Clinical Trials, Sparks
Advancing Research International, LLC, Los Angeles
Roski Eye Institute, Keck School of Medicine, USC, Los Angeles
Alliance Research Institute - Lynwood, Lynwood
United Medical Research Institute, Inglewood
Pasadena Clinical Trials, Pasadena
Alliance Research Institute - Canoga Park, Canoga Park
Senta Clinic, San Diego
Marvel Clinical Research, Huntington Beach
A.P.J. Office, Newport Beach
Byers Eye Institute at Stanford University, Palo Alto
University of Washington, Eye institute, Seattle
Massachusetts Eye and Ear, Boston
Opthalmic Consultants of Boston, East Weymouth
Rutgers New Jersey Medical School, Newark
Viridian Therapeutics, Inc.
INDUSTRY